Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a phase II randomized study from the Belgian Hematology Society (BHS)

You likely can't join if

• Exclusion criteria: • Any condition not fulfilling inclusion criteria; • HIV positive; • Non-hematological malignancy(ies) (except non-melanoma skin cancer) active < 3 years before HCT. • Life expectancy severely limited by disease other than malignancy; • CNS involvement with disease refractory to intrathecal chemotherapy. • Terminal organ failure, except for renal failure (dialysis acceptable) a. Cardiac: Symptomatic coronary artery disease; ejection fraction <40%; uncontrolled arrhythmia, uncontrolled hypertension; b. Pulmonary: DLCO < 40% and/or receiving supplementary continuous oxygen, FEV1< 40%; c. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dL, and symptomatic biliary disease; • Uncontrolled infection; • Karnofsky Performance Score <70%; • Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment; • Patient is a female who is pregnant or breastfeeding; • Any condition precluding the use of melphalan or ATG